PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Andiroba gel was evaluated for therapeutic effects on symptomatology and evolution of oral mucositis in children with leukemia undergoing chemotherapy [PMID:32920135]
Gedunin-type limonoids exhibited hepatoprotective effects against d-galactosamine/lipopolysaccharide-induced liver injury [PMID:27104518]
Andiroba oil and its limonoid-rich fraction inhibited the growth of W(2) clones by 100% and Dd(2) clones by 88% [PMID:22659195]
Andiroba oil demonstrated healing activity against 5-fluorouracil induced oral mucositis [PMID:29256157, PMID:36634224]
Andiroba oil promotes apoptosis in gastric cancer cells at high concentrations [PMID:37020602, PMID:32150766]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 38432579 (2024) — Effects of andiroba oil (Carapa guianensis aublet) on the immune system in inflammation and wound healing: A scoping review. · Journal of ethnopharmacology
- 2.PMID: 27104518 (2016) — Hepatoprotective Limonoids from Andiroba (Carapa guianensis). · International journal of molecular sciences
- 3.PMID: 34069314 (2021) — PCL/Andiroba Oil (Carapa guianensis Aubl.) Hybrid Film for Wound Healing Applications. · Polymers
- 4.PMID: 23701562 (2014) — The therapeutic properties of Carapa guianensis. · Current pharmaceutical design
- 5.PMID: 22659195 (2012) — Antiplasmodial activity of the andiroba (Carapa guianensis Aubl., Meliaceae) oil and its limonoid-rich fraction.